NEVRO ($NVRO) posted quarterly earnings results on Tuesday, March 4th. The company reported earnings of -$0.64 per share, beating estimates of -$0.79 by $0.15. The company also reported revenue of $105,550,000, beating estimates of $104,594,880 by $955,120.
You can see Quiver Quantitative's $NVRO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NEVRO Hedge Fund Activity
We have seen 68 institutional investors add shares of NEVRO stock to their portfolio, and 101 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ENGAGED CAPITAL LLC removed 2,442,956 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $9,087,796
- SHAY CAPITAL LLC added 932,732 shares (+617.2%) to their portfolio in Q4 2024, for an estimated $3,469,763
- CANTOR FITZGERALD, L. P. added 531,204 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,976,078
- BALYASNY ASSET MANAGEMENT L.P. removed 505,295 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,879,697
- NOMURA HOLDINGS INC removed 355,749 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,323,386
- WESTERN STANDARD LLC removed 333,840 shares (-34.1%) from their portfolio in Q4 2024, for an estimated $1,241,884
- EVERSEPT PARTNERS, LP removed 313,780 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,167,261
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NEVRO Government Contracts
We have seen $117,710 of award payments to $NVRO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- IMPLANT: $58,855
- PROS NEVRO POST SERGERY: $58,855
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
